Skip Navigation


European Heart Journal Advance Access originally published online on April 25, 2008
European Heart Journal 2008 29(12):1495-1503; doi:10.1093/eurheartj/ehn169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
29/12/1495    most recent
ehn169v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Widimsky, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widimsky, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8

Petr Widimsky1,*, Zuzana Motovská1, Stanislav Simek2, Petr Kala4, Radek Pudil3, Frantisek Holm5, Robert Petr1, Dana Bílková1, Hana Skalická2, Petr Kuchynka2, Martin Poloczek4, Roman Miklík4, Marek Maly6, Michael Aschermann on behalf of the PRAGUE-8 trial Investigators2

1 Third Medical Faculty and University Hospital Kralovske Vinohrady, Cardiocentre, Charles University, Srobárova 50, 100 34 Praha 10, Prague, Czech Republic
2 First Medical Faculty and General University Hospital, Cardiocentre, Charles University, Prague, Czech Republic
3 Medical Faculty and University Hospital Hradec Kralové, Cardiocentre, Charles University, Prague, Czech Republic
4 Masaryk University and University Hospital Brno, Brno, Czech Republic
5 Regional Hospital Liberec, Liberec, Czech Republic
6 National Institute of Public Health, Prague, Czech Republic

Received 11 October 2007; revised 12 March 2008; accepted 7 April 2008; online publish-ahead-of-print 25 April 2008.

* Corresponding author. Tel: +420 267163159, Fax: +420 267162621, Email: widim{at}fnkv.cz

See page 1475 for the editorial comment on this article (doi:10.1093/eurheartj/ehn230)

Aims: To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography (CAG)±ad hoc percutaneous coronary intervention (PCI).

Methods and results: Open-trial randomized 1028 patients with stable angina to group A (‘non-selective’—clopidogrel 600 mg >6 h before CAG; n = 513) or group B (‘selective’—clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; n = 515). Combined primary endpoint was death/periprocedural myocardial infarction (MI)/stroke/re-intervention within 7 days. Secondary endpoints were troponin elevation and bleeding complications. Primary endpoint occurred in 0.8% group A patients vs. 1% group B (P = 0.749; 90% CI for the percentage difference –1.2–0.8). Periprocedural troponin elevation (>3x ULN) was detected in 2.6% group A vs. 3.3% group B (P = 0.475; 90% CI –2.5–1.0). Bleeding complications occurred in 3.5% group A patients vs. 1.4% group B (P = 0.025). After adjustment for covariates and factors that may influence the bleeding risk, patients in group A were shown to have more likely bleeding complications when compared with group B (OR = 3.03; 95% CI 1.14–8.10; P = 0.027).

Conclusion: High (600 mg) loading dose of clopidogrel before elective CAG increased the risk of minor bleeding complications, while the benefit on periprocedural infarction was not significant. Clopidogrel can be given safely in the catheterization laboratory between CAG and PCI in chronic stable angina patients.

Key Words: Elective percutaneous coronary intervention • Clopidogrel pre-treatment • Stable coronary artery disease • Bleeding complications • Periprocedural ischaemic complications


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?
Francois Schiele, Nicolas Meneveau, and Jean-Pierre Bassand
EHJ 2008 29: 1475-1477. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
F. Schiele, N. Meneveau, and J.-P. Bassand
Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?
Eur. Heart J., June 2, 2008; 29(12): 1475 - 1477.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.